IL-22BP is produced by eosinophils in human gut and blocks IL-22 protective actions during colitis

Mucosal Immunology

Volumn 9, Issue 2, 2016, Pages 539-549

  Martin, J C ^a,b,c   Beriou G ^a   Heslan, M ^a   Bossard, C ^b,c,d   Jarry, A ^d   Abidi, A ^a   Hulin, P ^e   Menoret S ^a   Thinard, R ^a   Anegon, I ^a   Jacqueline, C ^b   Lardeux, B ^f   Halary, F ^a   Renauld, J C ^g,h   Bourreille, A ^c,f   Josien, R ^a,b,c  

^a Centre National de la Recherche Scientifique   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE NANTES   (France)

^e Recombinant Protein Production Facility Federative Research Structure François Bonamy   (France)

^f INSERM   (France)

^g LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^h DE DUVE INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CD103 ANTIGEN; CD11B ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; INTERLEUKIN 22; INTERLEUKIN 22 BINDING PROTEIN; MESSENGER RNA; MICROSOMAL AMINOPEPTIDASE; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; DEXTRAN SULFATE; IL22RA2 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; INTERLEUKIN RECEPTOR; INTERLEUKIN-22; INTERLEUKIN-22 RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL PROTECTION; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DOWN REGULATION; EOSINOPHIL; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MALE; MOLECULAR DYNAMICS; MUCOSAL INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS; UPREGULATION; ANIMAL; CASE CONTROL STUDY; CHEMICALLY INDUCED; COLON; DEFICIENCY; DISEASE MODEL; GENETICS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; SECRETION (PROCESS); SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TRANSGENIC RAT;

ADULT; ANIMALS; CASE-CONTROL STUDIES; COLITIS; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; EOSINOPHILS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; RECEPTORS, INTERLEUKIN; SIGNAL TRANSDUCTION;

EID: 84961859374     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2015.83     Document Type: Article

References (49)

1. Kaser A, Zeissig S, & Blumberg R.S. Inflammatory bowel disease. Annu. Rev. Immunol. 28, 573-621 (2010).
2. Sabat R, Ouyang W, & Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat. Rev. Drug. Discov. 13, 21-38 (2013).
3. Andoh A, et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology. 129, 969-984 (2005).
4. Brand S, et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G827-G838 (2006).
5. Schmechel S, et al. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm. Bowel. Dis. 14, 204-212 (2008).
6. Sugimoto K, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest. 118, 534-544 (2008).
7. Pariente B, et al. Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4+ T cells of patients with Crohn's disease. Gastroenterology. 141, 217-226 (2011).
8. Geremia A, et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J. Exp. Med. 208, 1127-1133 (2011).
9. Zenewicz L.A, et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity. 29, 947-957 (2008).
10. Pickert G, et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J. Exp. Med. 206, 1465-1472 (2009).
11. Monteleone I, et al. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology. 141, 237-248 (2011).
12. Zindl C.L, et al. IL-22-producing neutrophils contribute to antimicrobial defense and restitution of colonic epithelial integrity during colitis. Proc. Natl Acad. Sci. USA. 110, 12768-12773 (2013).
13. Mielke L.A, et al. Retinoic acid expression associates with enhanced IL-22 production by gd T cells and innate lymphoid cells and attenuation of intestinal inflammation. J. Exp. Med. 210, 1117-1124 (2013).
14. Xu W, et al. A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc. Natl Acad. Sci. USA. 98, 9511-9516 (2001).
15. Logsdon N.J, Jones B.C, Josephson K, Cook J, & Walter M.R. Comparison of interleukin-22 and interleukin-10 soluble receptor complexes. J. Interferon Cytokine Res. 22, 1099-1112 (2002).
16. Huber S, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature. 491, 259-263 (2012).
17. Martin J.C.J, et al. Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid. Mucosal Immunol. 7, 101-113 (2014).
18. Watchmaker P.B, et al. Comparative transcriptional and functional profiling defines conserved programs of intestinal DC differentiation in humans and mice. Nat. Immunol. 15, 98-108 (2014).
19. Jung Y, & Rothenberg M.E. Roles and regulation of gastrointestinal eosinophils in immunity and disease. J. Immunol. 193, 999-1005 (2014).
20. Dumoutier L, Lejeune D, Colau D, & Renauld J.C. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J. Immunol. 166, 7090-7095 (2001).
21. Hogan S.P, Waddell A, & Fulkerson P.C. Eosinophils in infection and intestinal immunity. Curr. Opin. Gastroenterol. 29, 7-14 (2013).
22. Gaudio E, et al. Dextran sulfate sodium (DSS) colitis in rats: clinical, structural, and ultrastructural aspects. Dig. Dis Sci. 44, 1458-1475 (1999).
23. Zenewicz L.A, et al. IL-22 deficiency alters colonic microbiota to be transmissible and colitogenic. J. Immunol. 190, 2306-2312 (2013).
24. Sonnenberg G.F, et al. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science. 336, 1321-1325 (2012).
25. Kleinschek M.A, et al. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J. Exp. Med. 206, 525-534 (2009).
26. Ramesh R, et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J. Exp. Med. 211, 89-104 (2014).
27. Longman R.S, et al. CX3CR1+ mononuclear phagocytes support colitisassociated innate lymphoid cell production of IL-22. J. Exp. Med. 211, 1571-1583 (2014).
28. Kamada N, et al. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J. Clin. Invest. 118, 2269-2280 (2008).
29. Begue B, et al. Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am. J. Gastroenterol. 106, 1544-1555 (2011).
30. Nakajima T, et al. Gene expression screening of human mast cells and eosinophils using high-density oligonucleotide probe arrays: abundant expression of major basic protein in mast cells. Blood. 98, 1127-1134 (2001).
31. Macpherson A.J, & McCoy K.D. Standardised animal models of host microbial mutualism. Mucosal Immunol. 8, 476-486 (2014).
32. Ivanov I.I, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 139, 485-498 (2009).
33. Gaboriau-Routhiau V, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity. 31, 677-689 (2009).
34. Spencer S.P, et al. Adaptation of innate lymphoid cells to a micronutrient deficiency promotes type 2 barrier immunity. Science. 343, 432-437 (2014).
35. Ueki S, et al. Retinoic acids up-regulate functional eosinophil-driving receptor CCR3. Allergy. 68, 953-956 (2013).
36. Lee J.J, et al. Human versus mouse eosinophils: 'that which we call an eosinophil, by any other namewould stain as red'. J. Allergy Clin. Immunol. 130, 572-584 (2012).
37. Chu V.T, et al. Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis. Immunity. 40, 582-593 (2014).
38. Goto Y, et al. Segmented filamentous bacteria antigens presented by intestinal dendritic cells drive mucosal Th17 cell differentiation. Immunity. 40, 594-607 (2014).
39. Kamada N, Seo S.-U, Chen G.Y, & Núñ ez G. Role of the gutmicrobiota in immunity and inflammatory disease. Nat. Rev. Immunol. 13, 321-335 (2013).
40. Kryczek I, et al. IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity. 40, 772-784 (2014).
41. Kamanaka M, et al. Memory/effector (CD45RB(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J. Exp. Med. 208, 1027-1040 (2011).
42. Eken A., Singh A.K, Treuting, P.M. &Oukka M. IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism. Mucosal Immunol. 7, 143-154 (2014).
43. Vonarbourg C, et al. Regulated expression of nuclear receptor RORgt confers distinct functional fates to NK cell receptor-expressing RORgt(+) innate lymphocytes. Immunity. 33, 736-751 (2010).
44. Zheng Y, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med. 14, 282-289 (2008).
45. Moriwaki K, et al. The Necroptosis Adaptor RIPK3 Promotes Injury-Induced Cytokine Expression and Tissue Repair. Immunity. 41, 567-578 (2014).
46. Zelante T, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 39, 372-385 (2013).
47. Geurts A.M, et al. Knockout rats via embryo microinjection of zinc-finger nucleases. Science. 325, 433 (2009).
48. Maxwell J.R, Brown, W.A, Smith C.L, Byrne F.R, & Viney J.L. Methods of inducing inflammatory bowel disease in mice. Curr. Protoc. Pharmacol, Chapter. 5, Unit 5.58 (2009).
49. Jarry A, et al. Mucosal IL-10 and TGF-beta play crucial roles in preventing LPS-driven, IFN-gamma-mediated epithelial damage in human colon explants. J. Clin. Invest. 118, 1132-1142 (2008).